One more in a pile of lawsuits has been filed against the makers of the type 2 diabetes drug Invokana; namely Johnson and Johnson and their subsidiary Jansen Pharmaceutical. In this new case, filed on June 1st, 2016 in the U.S. District Court for the District of New Jersey, it is alleged that the plaintiff, Judy Thompson, suffered multiple severe side effects, which include stroke, diabetic ketoacidosis and kidney damage. The suit accuses the defendants of failing to warn of the side effects, negligence and misrepresentation.
Judy Thompson claims in her suit that she suffered the detrimental side effects after taking Invokana between February 2015 and June 2015.
Thompson claims, as have a large and increasing number of plaintiffs, that the makers of Invokana should have known of the dangerous side effects of the drug but failed to provide adequate warnings in an attempt to protect their own profits. It is also alleged in her suit that the potential for severe side effects were deemphasized while aggressive marketing campaigns exaggerated the potential benefits of Invokana.
Judy Thompson’s Invokana lawsuit makes the following claim:
“The development of Plaintiff’s injuries was preventable and resulted directly form Defendants failure and refusal to conduct proper safety studies, failure to properly assess and publicize alarming safety signals, suppression of information revealing serious and life-threatening risks, willful and wanton failure to provide adequate instructions, and willful misrepresentation concerning the nature and safety of Invokana. This conduct as well as the product defects complained of herein, were substantial factors in bringing about and exacerbating Plaintiffs injuries.”
Prior to FDA approval, a New York Times article reported that the drug was associated with an elevated risk of stroke in clinical trials.
As the first member of the SGL2T inhibitor class of type 2 diabetes drugs, Invokana received FDA approval in March of 2013 and rapidly gained in popularity. Less than two years later the FDA warned against serious and potentially fatal side effects including diabetic ketoacidosis, a dangerous accumulation of acids called ketones in the blood of SGLT2 inhibitor users. A second such warning was issued in December of 2015. Also in December of 2015 the FDA issued a warning to doctors and patients that SGLT2 inhibitors, including Invokana, may increase the risk of urinary tract infections significantly. If not treated in a timely manner, these infections could lead to urosepsis or pyelonephritis (blood poisoning or kidney infections) which may result in sepsis, kidney damage, organ failure and death in some cases. More recent warnings by the FDA indicate that Invokana and related drugs may increase the risk of bone fractures and also raise a higher risk of diabetic amputations of the toe, foot and leg.
Invokana Lawsuits are Piling Up
With the increasing number of possible severe side effects associated with Invokana and other SGLT2 inhibitor drugs, the number of persons seeking compensatory damages for injuries to themselves or loved ones is rapidly increasing also. Sibley Dolman Gipe Accident Injury Lawyers, PA is currently seeking individuals who have suffered from apparent detrimental effects of these drugs. If you or someone you care about has suffered, the defective drug attorneys at Dolman Law would like to speak with you. You may be entitled to compensation for medical bills, lost income as well as pain and suffering and more. Reach out to Sibley Dolman Gipe Accident Injury Lawyers, PA today at (833) 606-DRUG . There is no cost to speak with an attorney for an evaluation of your case.
Sibley Dolman Gipe Accident Injury Lawyers, PA
800 North Belcher Road
Clearwater, FL 33765
(833) 606-DRUG